CCOA Biotechnology is a state-of-the-art technology platform operating within CCOA Therapeutics Inc. that provides life science services, diagnostics and research reagents. Housed at Unity Health Toronto, St. Michael's Hospital, CCOA Biotechnology generates high-quality antibodies, kits and reagents for research use which have been utilized in many high impact publications for over twenty years.
Glycoprotein Ibα (GPIbα), also known as CD42b, is a component of the GPIb-V-IX complex on platelets. The GPIb-V-IX complex binds von Willebrand factor, allowing platelet adhesion and platelet plug formation at sites of vascular injury. These anti-CD42b monoclonal antibodies are generated in hybridoma cells isolated from GPIbα knockout mice immunized with wild-type mouse platelets.
Anti-CD61 (β3, GPIIIa)
Antigen CD61, also known as β3 integrin, is an integrin family protein comprised of αIIb/αV and β3 subunits that performs both outside-in and inside-out signalling contributing to cell adhesion. Our anti-CD61 monoclonal antibodies are generated in hybridoma cells isolated from β3 knockout mice immunized with purified recombinant human β3 integrin.
Antibody epitope mapping
Stable cell line generation
Transfection-grade plasmid preparation
Antibody affinity maturation
Custom Antibody Development